MediWound Ltd. (MDWD) Expected to Post Quarterly Sales of $740,000.00

Analysts expect that MediWound Ltd. (NASDAQ:MDWD) will report $740,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for MediWound’s earnings. The lowest sales estimate is $600,000.00 and the highest is $820,000.00. MediWound reported sales of $520,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 42.3%. The company is expected to issue its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that MediWound will report full-year sales of $740,000.00 for the current fiscal year, with estimates ranging from $2.50 million to $3.40 million. For the next year, analysts anticipate that the company will report sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for MediWound.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. During the same quarter last year, the business earned ($0.34) earnings per share. MediWound’s quarterly revenue was up 93.8% on a year-over-year basis.

Several analysts have recently issued reports on the company. Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Jefferies Group LLC set a $10.00 price objective on MediWound and gave the company a “buy” rating in a research report on Friday, August 25th. Cowen and Company assumed coverage on MediWound in a research report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. ValuEngine downgraded MediWound from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Finally, SunTrust Banks, Inc. restated a “buy” rating on shares of MediWound in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.15.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/10/10/mediwound-ltd-mdwd-expected-to-post-quarterly-sales-of-740000-00.html.

MediWound (NASDAQ:MDWD) traded down 2.91% during trading on Friday, reaching $5.00. The company’s stock had a trading volume of 27,139 shares. The company’s market cap is $109.77 million. The company’s 50 day moving average price is $5.69 and its 200 day moving average price is $6.42. MediWound has a 52 week low of $4.25 and a 52 week high of $8.25.

A number of institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. increased its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after purchasing an additional 342,165 shares during the last quarter. Wells Fargo & Company MN increased its stake in MediWound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the last quarter. Renaissance Technologies LLC increased its stake in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after purchasing an additional 213,745 shares during the last quarter. Hedge funds and other institutional investors own 19.55% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWoun

On average, analysts expect that MediWound will report full-year sales of $740,000.00 for the current fiscal year, with estimates ranging from $2.50 million to $3.40 million. For the next year, analysts anticipate that the company will report sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for MediWound.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.69 million. During the same quarter last year, the business earned ($0.34) earnings per share. MediWound’s quarterly revenue was up 93.8% on a year-over-year basis.

Several analysts have recently issued reports on the company. Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Jefferies Group LLC set a $10.00 price objective on MediWound and gave the company a “buy” rating in a research report on Friday, August 25th. Cowen and Company assumed coverage on MediWound in a research report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. ValuEngine downgraded MediWound from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd. Finally, SunTrust Banks, Inc. restated a “buy” rating on shares of MediWound in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.15.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/10/10/mediwound-ltd-mdwd-expected-to-post-quarterly-sales-of-740000-00.html.

MediWound (NASDAQ:MDWD) traded down 2.91% during trading on Friday, reaching $5.00. The company’s stock had a trading volume of 27,139 shares. The company’s market cap is $109.77 million. The company’s 50 day moving average price is $5.69 and its 200 day moving average price is $6.42. MediWound has a 52 week low of $4.25 and a 52 week high of $8.25.

A number of institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. increased its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after purchasing an additional 342,165 shares during the last quarter. Wells Fargo & Company MN increased its stake in MediWound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the last quarter. Renaissance Technologies LLC increased its stake in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after purchasing an additional 213,745 shares during the last quarter. Hedge funds and other institutional investors own 19.55% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply